Dysregulated expression of stem cell factor Bmi1 in precancerous lesions of the gastrointestinal tract

被引:61
作者
Tateishi, Keisuke
Ohta, Miki
Kanai, Fumihiko
Guleng, Bayasi
Tanaka, Yasuo
Asaoka, Yoshinari
Tada, Motohisa
Seto, Motoko
Jazag, Amarsanaa
Lianjie, Lin
Okamoto, Makoto
Isayama, Hiroyuki
Tada, Minoru
Yoshida, Haruhiko
Kawabe, Takao
Omata, Masao
机构
[1] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan
[2] Univ Tokyo, Grad Sch Med, Dept Clin Drug Evaluat, Tokyo, Japan
关键词
D O I
10.1158/1078-0432.CCR-06-0449
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: It is important to identify the definitive molecular switches involved in the malignant transformation of premalignant tissues. Cellular senescence is a specific characteristic of precancerous tissues, but not of cancers, which might reflect tumorigenesis-protecting mechanisms in premalignant lesions. Polycomb protein Bmi1, which is a potent negative regulator of the p16INK4 gene, suppresses senescence in primary cells and is overexpressed in various cancers. We hypothesized that Bmi1 expression would also be dysregulated in precancerous lesions in human digestive precancerous tissues. Experimental Design: Bmi1 expression was investigated in cancerous and precancerous tissues of the digestive tract. The expression of p16, beta-catenin, and Gli1 and the in vivo methylation status of the p16 gene were also analyzed in serial sections of colonic precancerous lesions. Results: Bmi1 was clearly overexpressed across a broad spectrum of gastrointestinal cancers, and the expression of Bmi1 increased in a manner that reflected the pathologic malignant features of precancerous colonic tissues (low-grade dysplasia, 12.9 +/- 2.0%; high-grade dysplasia, 82.9 +/- 1.6%; cancer, 87.5 +/- 2.4%). p16 was also strongly expressed in high-grade dysplasia, but not in cancers. p16 promoter methylation was detected only in some Bmi1-positive neoplastic cells. Conclusions: Bmi1 overexpression was correlated with the malignant grades of human digestive precancerous tissues, which suggests that advanced Bmi1 dysregulation might predict malignant progression. The abnormal Bmi1 expression might link to malignant transformation via the disturbance of orderly histone modification.
引用
收藏
页码:6960 / 6966
页数:7
相关论文
共 54 条
[51]   The polycomb group protein EZH2 is involved in progression of prostate cancer [J].
Varambally, S ;
Dhanasekaran, SM ;
Zhou, M ;
Barrette, TR ;
Kumar-Sinha, C ;
Sanda, MG ;
Ghosh, D ;
Pienta, KJ ;
Sewalt, RGAB ;
Otte, AP ;
Rubin, MA ;
Chinnaiyan, AM .
NATURE, 2002, 419 (6907) :624-629
[52]   The Polycomb group protein EZH2 directly controls DNA methylation [J].
Viré, E ;
Brenner, C ;
Deplus, R ;
Blanchon, L ;
Fraga, M ;
Didelot, C ;
Morey, L ;
Van Eynde, A ;
Bernard, D ;
Vanderwinden, JM ;
Bollen, M ;
Esteller, M ;
Di Croce, L ;
de Launoit, Y ;
Fuks, F .
NATURE, 2006, 439 (7078) :871-874
[53]   The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma [J].
Visser, HPJ ;
Gunster, MJ ;
Kluin-Nelemans, HC ;
Manders, EMM ;
Raaphorst, FM ;
Meijer, CJLM ;
Willemze, R ;
Otte, AP .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (04) :950-958
[54]   The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression [J].
Vonlanthen, S ;
Heighway, J ;
Altermatt, HJ ;
Gugger, M ;
Kappeler, A ;
Borner, MM ;
van Lohuizen, M ;
Betticher, DC .
BRITISH JOURNAL OF CANCER, 2001, 84 (10) :1372-1376